文献速递血液淋巴病理

WHO第五版成熟B细胞肿瘤分类:研究中的开放问题

The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research.
PubMed 文献 · J Pathol · 2024-01-05

本文综述WHO-HAEM5成熟B细胞肿瘤分类中需进一步研究的争议领域,包括脾B细胞淋巴瘤/白血病伴显著核仁的暂定命名、BCL2重排阴性滤泡性淋巴瘤的分类、MYC易位非IG伙伴基因的影响,以及高级别B细胞淋巴瘤的界定。

要点

  • 脾B细胞淋巴瘤/白血病伴显著核仁为暂定术语,涵盖既往毛细胞白血病变异型和B幼淋巴细胞白血病。
  • BCL2重排阴性滤泡性淋巴瘤(含BCL6重排)分类需整合生发中心B细胞亚群新知识。
  • 需明确MYC易位非IG伙伴基因谱及其对MYC表达和临床结局的影响。

核心结论

  • WHO-HAEM5基于证据更新,但部分实体和亚型分类仍需进一步研究以优化诊断和预后分层。

研究设计与样本

  • 本文为综述,基于WHO-HAEM5分类的制定背景,选取挑战性领域进行讨论以促进研究。

主要发现

  • 脾B细胞淋巴瘤/白血病伴显著核仁作为暂定术语,涵盖既往毛细胞白血病变异型和B幼淋巴细胞白血病。
  • BCL2重排阴性滤泡性淋巴瘤包括BCL6重排者,需整合生发中心B细胞亚群新知识进行分类。
  • 弥漫大B细胞淋巴瘤/高级别B细胞淋巴瘤中MYC易位的非IG伙伴基因谱及其对MYC表达和临床结局的影响待研究。
  • 高级别B细胞淋巴瘤非特指型和伴11q异常的高级别B细胞淋巴瘤需更好定义以区分 mimic 并表征分子机制。

临床怎么用

  • 病理科医生应关注这些开放问题,在诊断中结合分子检测和临床信息,对暂定术语保持审慎。

局限性

  • 本文为综述,未提供新的原始数据或系统评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The fifth edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO-HAEM5) is the product of an evidence-based evolution of the revised fourth edition with wide multidisciplinary consultation. Nonetheless, while every classification incorporates scientific advances and aims to improve upon the prior version, medical knowledge remains incomplete and individual neoplasms may not be easily subclassified in a given scheme. Thus, optimal classification requires ongoing study, and there are certain aspects of some entities and subtypes that require further refinements. In this review, we highlight a selection of these challenging areas to prompt more research investigations. These include (1) a 'placeholder term' of splenic B-cell lymphoma/leukaemia with prominent nucleoli (SBLPN) to accommodate many of the splenic lymphomas previously classified as hairy cell leukaemia variant and B-prolymphocytic leukaemia, a clear new start to define their pathobiology; (2) how best to classify BCL2 rearrangement negative follicular lymphoma including those with BCL6 rearrangement, integrating the emerging new knowledge on various germinal centre B-cell subsets; (3) what is the spectrum of non-IG gene partners of MYC translocation in diffuse large B-cell lymphoma/high-grade B-cell lymphoma and how they impact MYC expression and clinical outcome; how best to investigate this in a routine clinical setting; and (4) how best to define high-grade B-cell lymphoma not otherwise specified and high-grade B-cell lymphoma with 11q aberrations to distinguish them from their mimics and characterise their molecular pathogenetic mechanism. Addressing these questions would provide more robust evidence to better define these entities/subtypes, improve their diagnosis and/or prognostic stratification, leading to better patient care. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

来源:J Pathol,查看原文。版权归原作者所有。

引用

  1. Coupland SE, Du MQ, Ferry JA, et al. The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research. J Pathol. 2024. PMID: 38180354. doi:10.1002/path.6246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。